Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-003 in Chronic Hepatitis B
NCT06661148Phase 1Not yet recruiting
- Sponsor
- Epigenic Therapeutics
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of EPI-003 in Chronic Hepatitis B (CHB), sponsored by Epigenic Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) at Day 28. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
EPI-003
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06661148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06661148.